Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 31, 2015, Pages 9734-9739

  Zhang, Xueli ^a,b,c   Tian, Yanli ^a,d   Zhang, Can ^a   Tian, Xiaoyu ^e   Ross, Alana W ^a   Moir, Robert D ^a   Sun, Hongbin ^b   Tanzi, Rudolph E ^a   Moore, Anna ^a   Ran, Chongzhao ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's; Amyloid; Curcumin; Fluorescence; Imaging

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; CRANAD 17; CRANAD 3; CURCUMIN; IMIDAZOLE; LY 2811376; UNCLASSIFIED DRUG; FLUORESCENT DYE; PRESENILIN 1; THIAZOLE DERIVATIVE; THIOFLAVINE; TISSUE EXTRACT;

AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IMAGING; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MOLECULAR PATHOLOGY; MOUSE; NEAR INFRARED FLUORESCENCE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; ANIMAL; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMISTRY; DISEASE MODEL; DRUG MONITORING; HUMAN; METABOLISM; MOLECULAR IMAGING; NEAR INFRARED SPECTROSCOPY; PHOTON; PROCEDURES; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROFLUOROMETRY; SYNTHESIS; TITRIMETRY; TRANSGENIC MOUSE;

ANIMALIA; MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CARBON-13 MAGNETIC RESONANCE SPECTROSCOPY; DISEASE MODELS, ANIMAL; DRUG MONITORING; FLUORESCENT DYES; HUMANS; MICE, TRANSGENIC; MOLECULAR IMAGING; PHOTONS; PRESENILIN-1; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, NEAR-INFRARED; THIAZOLES; TISSUE EXTRACTS; TITRIMETRY;

EID: 84938770048     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1505420112     Document Type: Article

References (84)

1. Giacobini E, Gold G (2013) Alzheimer disease therapy-moving from amyloid-β to tau. Nat Rev Neurol 9(12):677-686.
2. Selkoe DJ (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17(9):1060-1065.
3. Abbott A (2008) Neuroscience: The plaque plan. Nature 456(7219):161-164.
4. Buckholtz NS, Ryan LM, Petanceska S, Refolo LM (2012) NIA commentary: Translational issues in Alzheimer's disease drug development. Neuropsychopharmacology 37(1):284-286.
5. Jonsson T, et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488(7409):96-99.
6. Castellani RJ, et al. (2009) Reexamining Alzheimer's disease: Evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 18(2):447-452.
7. Kim T, et al. (2013) Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 341(6152):1399-1404.
8. John V, ed (2010) BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease (Wiley, Hoboken, NJ).
9. Faux NG, et al. (2010) PBT2 rapidly improves cognition in Alzheimer's Disease: Additional phase II analyses. J Alzheimers Dis 20(2):509-516.
10. Monceaux CJ, et al. (2011) Triazole-linked reduced amide isosteres: An approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors. Bioorg Med Chem Lett 21(13):3992-3996.
11. Lee J, et al. (2011) Identification of presenilin 1-selective γ-secretase inhibitors with reconstituted γ-secretase complexes. Biochemistry 50(22):4973-4980.
12. Barrow JC, et al. (2008) Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. J Med Chem 51(20):6259-6262.
13. Zhang MR, et al. (2005) Synthesis and evaluation of N-(5-fluoro-2-phenoxyphenyl)-N-(2-[(18)F]fluoromethoxy-d(2)-5-methoxybenzyl)acetamide: A deuterium-substituted radioligand for peripheral benzodiazepine receptor. Bioorg Med Chem 13(5):1811-1818.
14. Sperling RA, et al. (2014) The A4 study: Stopping AD before symptoms begin? Sci Transl Med 6(228):228fs13.
15. Choi SH, et al. (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515(7526):274-278.
16. McLean CA, et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46(6):860-866.
17. Lue LF, et al. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155(3):853-862.
18. Terry RD, et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4): 572-580.
19. Townsend M, Mehta T, Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282(46): 33305-33312.
20. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101(5):1172-1184.
21. Shankar GM, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8):837-842.
22. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297(5580):353-356.
23. Mawuenyega KG, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012):1774-1776.
24. Hsiao K, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284):99-102.
25. Cao D, Lu H, Lewis TL, Li L (2007) Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282(50):36275-36282.
26. Kantarci K, et al. (2012) Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 33(5):878-885.
27. Ikonomovic MD, et al. (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131(Pt 6):1630-1645.
28. Kalaitzakis ME, Pearce RK (2013) Beyond the limits of detection: Failure of PiB imaging to capture true Aβ burden. Mov Disord 28(3):406.
29. Gomperts SN, Johnson KA, Growdon J (2013) Reply: Beyond the limits of detection: Failure of PiB imaging to capture true Aβ burden. Mov Disord 28(3):407.
30. Mathis CA, Mason NS, Lopresti BJ, Klunk WE (2012) Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med 42(6):423-432.
31. Zhang L, Chang RC, Chu LW, Mak HK (2012) Current neuroimaging techniques in Alzheimer's disease and applications in animal models. Am J Nucl Med Mol Imaging 2(3):386-404.
32. Kuntner C, et al. (2009) Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol 11(4):236-240.
33. Nordberg A (2011) Molecular imaging in Alzheimer's disease: New perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 3(6):34.
34. Jack CR, Jr, et al. (2004) In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 52(6):1263-1271.
35. Klunk WE, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55(3):306-319.
36. Nordberg A, Rinne JO, Kadir A, Långström B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6(2):78-87.
37. Jakob-Roetne R, Jacobsen H (2009) Alzheimer's disease: From pathology to therapeutic approaches. Angew Chem Int Ed Engl 48(17):3030-3059.
38. Chang WM, et al. (2011) ANCA: A family of fluorescent probes that bind and stain amyloid plaques in human tissue. ACS Chem Neurosci 2(5):249-255.
39. Choi SR, et al. (2009) Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. J Nucl Med 50(11):1887-1894.
40. Li Q, et al. (2004) Solid-phase synthesis of styryl dyes and their application as amyloid sensors. Angew Chem Int Ed Engl 43(46):6331-6335.
41. Hintersteiner M, et al. (2005) In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 23(5):577-583.
42. Cui M, Ono M, Kimura H, Liu B, Saji H (2011) Synthesis and structure-affinity relationships of novel dibenzylideneacetone derivatives as probes for β-amyloid plaques. J Med Chem 54(7):2225-2240.
43. Cui M, et al. (2014) Smart near-infrared fluorescence probes with donor-acceptor structure for in vivo detection of β-amyloid deposits. J Am Chem Soc 136(9): 3388-3394.
44. Ono M, Watanabe H, Kimura H, Saji H (2012) BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques. ACS Chem Neurosci 3(4):319-324.
45. Ran C, Zhao W, Moir RD, Moore A (2011) Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta species. PLoS One 6(4):e19362.
46. Zhang X, et al. (2013) Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. J Am Chem Soc 135(44):16397-16409.
47. Ran C, et al. (2009) Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. JAm Chem Soc 131(42):15257-15261.
48. Hanyu M, et al. (2005) Studies on intramolecular hydrogen bonding between the pyridine nitrogen and the amide hydrogen of the peptide: Synthesis and conformational analysis of tripeptides containing novel amino acids with a pyridine ring. J Pept Sci 11(8):491-498.
49. Rzepecki P, Schrader T (2005) beta-Sheet ligands in action: KLVFF recognition by aminopyrazole hybrid receptors in water. J Am Chem Soc 127(9):3016-3025.
50. Kayed R, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300(5618):486-489.
51. Wu JW, et al. (2010) Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J Biol Chem 285(9):6071-6079.
52. Kayed R, et al. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2:18.
53. Schilling S, et al. (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45(41):12393-12399.
54. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 267(24):17082-17086.
55. Marshall KE, Serpell LC (2009) Structural integrity of beta-sheet assembly. Biochem Soc Trans 37(Pt 4):671-676.
56. Garcia-Alloza M, et al. (2006) Characterization of amyloid deposition in the APPswe/ PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24(3):516-524.
57. Zhang X, et al. (2014) A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer's disease. Chem Commun (Camb) 50(78):11550-11553.
58. Smith EE, Greenberg SM (2009) Beta-amyloid, blood vessels, and brain function. Stroke 40(7):2601-2606.
59. de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3(3):184-190.
60. May PC, et al. (2011) Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 31(46):16507-16516.
61. Zhang C, Browne A, Child D, Tanzi RE (2010) Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 285(37):28472-28480.
62. Wagner SL, et al. (2014) Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species. Biochemistry 53(4):702-713.
63. Veeraraghavalu K, et al. (2013) Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340(6135): 924-f.
64. Maruyama M, et al. (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79(6):1094-1108.
65. Landreth GE, et al. (2013) Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340(6135):924-g.
66. Tesseur I, et al. (2013) Comment on "ApoE-directed therapeutics rapidly clear betaamyloid and reverse deficits in AD mouse models". Science 340(6135):924-e.
67. Price AR, et al. (2013) Comment on "ApoE-directed therapeutics rapidly clear betaamyloid and reverse deficits in AD mouse models". Science 340(6135):924-d.
68. Fitz NF, Cronican AA, Lefterov I, Koldamova R (2013) Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science 340(6135):924-c.
69. Cramer PE, et al. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335(6075):1503-1506.
70. Sheline YI, et al. (2014) An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med 6(236):236re4.
71. Kounnas MZ, et al. (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67(5): 769-780.
72. Bacskai BJ, et al. (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 100(21):12462-12467.
73. Nesterov EE, et al. (2005) In vivo optical imaging of amyloid aggregates in brain: Design of fluorescent markers. Angew Chem Int Ed Engl 44(34):5452-5456.
74. Grutzendler J, Yang G, Pan F, Parkhurst CN, Gan WB (2011) Transcranial two-photon imaging of the living mouse brain. Cold Spring Harb Protoc 2011(9):pdb.prot065474.
75. Ashe KH, Zahs KR (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66(5):631-645.
76. Howlett DR (2011) APP transgenic mice and their application to drug discovery. Histol Histopathol 26(12):1611-1632.
77. Snellman A, et al. (2013) Longitudinal amyloid imaging in mouse brain with 11C-PIB: Comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med 54(8):1434-1441.
78. Maeda J, et al. (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27(41):10957-10968.
79. Mori T, et al. (2012) Molecular imaging of dementia. Psychogeriatrics 12(2):106-114.
80. Weissleder R, Pittet MJ (2008) Imaging in the era of molecular oncology. Nature 452(7187):580-589.
81. Luker GD, Luker KE (2008) Optical imaging: Current applications and future directions. J Nucl Med 49(1):1-4.
82. Moir RD, et al. (2005) Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 280(17): 17458-17463.
83. Mostany R, Portera-Cailliau C (2008) A craniotomy surgery procedure for chronic brain imaging. J Vis Exp (12):pii680.
84. Borchelt DR, et al. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17(5):1005-1013.